{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:29:40Z","timestamp":1789655380125,"version":"4.0.1"},"reference-count":21,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Introduction: Rituximab is a monoclonal chimeric antibody against CD20+ B cells. We aimed to assess the long-term efficacy and safety of CD20+ B cell-guided treatment with low-dose rituximab in refractory myasthenia gravis patients. Methods: Patients with refractory myasthenia gravis treated with rituximab for more than 2 years were included. Rituximab was administered when CD20+ B cells were greater than 1%. We analysed the efficacy of rituximab, treatment interval, side effects, prognosis, and treatment course. Results: A total of 22 patients were included. All patients received 2\u201312 doses of rituximab, and the median follow-up time was 48.5 months. The scores of the Myasthenia Gravis Activities of Daily Living and Myasthenia Gravis Composite were significantly lower than those at baseline (p &amp;lt; 0.05). MGFA-PIS was significantly improved in 21 (95.45%) patients and 14 (63.64%) patients have reached MGFA-PIS minimal manifestations. The average daily dose of prednisone and pyridostigmine bromide and the proportion of immunosuppressants were significantly lower (p &amp;lt; 0.05). Seven patients suffered from 14 worsenings. Eight patients terminated rituximab due to good efficacy. Most patients tolerated rituximab well, although 1 patient had opportunistic infection and hypogammaglobulinemia, 1 patient had an intracranial mass. Conclusion: Long-term CD20+ B-cell-guided low-dose rituximab showed good efficacy and tolerance in patients with refractory myasthenia gravis.<\/jats:p>","DOI":"10.1159\/000534336","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T17:02:04Z","timestamp":1698426124000},"page":"387-394","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis"],"prefix":"10.1159","volume":"86","author":[{"given":"Jingru","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23839"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu463"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.12.004"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.05.021"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26790"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319410"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001126"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000410"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05042-3"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.637932"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101933"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8771-5"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200288"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000272"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.05.013"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150051"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2015.05.009"}],"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ene\/article-pdf\/86\/6\/387\/4062048\/000534336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ene\/article-pdf\/86\/6\/387\/4062048\/000534336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:45:50Z","timestamp":1745408750000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000534336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12,18]]},"published-print":{"date-parts":[[2023,12,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000534336","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"value":"0014-3022","type":"print"},{"value":"1421-9913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}